• Shaped ABC Coil-Bottlebrush Terpolymer Self-Assembly

  2026-08-21

  This study examines how sequence and side-chain shape control the phase behavior of ABC coil–bottlebrush triblock terpolymers. SAXS revealed robust segregation but unexpected suppression of double-gyroid formation and unusually slow structural ordering, providing design constraints for large-period network materials.

• Topotecan HCl: From DNA Lesions to Translation

  2026-08-20

  Topotecan HCl is more than a cytotoxic reagent: it is a controllable probe of replication-associated DNA damage, response kinetics, and treatment scheduling. This thought-leadership guide connects topoisomerase 1 biology with assay design, model selection, toxicity interpretation, and translational strategy.

• CHIR-99021 Workflows for Stem Cell Differentiation

  2026-08-20

  CHIR-99021 (CT99021) gives researchers a controllable way to tune GSK-3 activity across pluripotency, neural crest, corneal endothelial, and cardiac differentiation workflows. This guide translates Wnt timing, reagent handling, assay checkpoints, and troubleshooting into practical experimental decisions.

• Resazurin Sodium Salt: Mechanism and Assay Use

  2026-08-19

  Resazurin sodium salt is a fluorogenic oxidation-reduction indicator for metabolic cell proliferation and cytotoxicity measurements. Its reduction to fluorescent resorufin supports scalable viability workflows, but exposure time, concentration, solvent, and product accumulation can affect interpretation.

• Abiraterone acetate in 3D Prostate Cancer Models

  2026-08-19

  Use Abiraterone acetate as a mechanistically focused CYP17 inhibitor in prostate cancer assays, then test whether androgen pathway suppression translates into changes in patient-derived 3D spheroids. This workflow pairs biochemical exposure control with orthogonal viability, PSA, AR, and tissue-marker readouts to distinguish pathway resistance from delivery or assay failure.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-18

  The 2025 Cancer Letters review integrates tumor hypoxia, nutrient competition, and immune-cell metabolic dysfunction into a unified model of immunosuppressive tumor-microenvironment formation. Its main practical contribution is a framework for connecting HIF signaling and glucose-centered metabolic adaptation with immune evasion, while identifying both opportunities and limitations for metabolism-based therapies.

• Ridaforolimus Workflows for mTOR Cancer Research

  2026-08-18

  Build reproducible mTOR signaling, proliferation, apoptosis, and angiogenesis workflows with Ridaforolimus (Deforolimus, MK-8669). This guide connects dose-controlled cancer assays with machine-learning-informed senescence experiments while emphasizing controls, interpretation, and troubleshooting.

• Gemcitabine: DNA Damage and Cancer Assays

  2026-08-17

  Gemcitabine is a fluorinated deoxycytidine analog and DNA synthesis inhibitor used in cancer research, apoptosis assays, and DNA damage response studies. Its product-reported checkpoint activity and preclinical anti-tumor effects complement evidence that metabolic intervention can improve gemcitabine and cisplatin responses in cholangiocarcinoma.

• The 4Q Principle for Stable mRNA Delivery

  2026-08-17

  Shi and colleagues introduced a 4Q framework that separates mRNA delivery into vector stability, tissue diffusion, cellular entry, and intracellular release. Their polycatechol-based PBD system formed mRNA polyplexes that remained stable at room temperature for more than two weeks and produced substantially higher in vivo reporter output than a jetPEI benchmark.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-08-16

  The reference review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its rapid, predictable anticoagulant activity and reduced dependence on INR monitoring. Its prodrug design, renal-function considerations, and evidence across venous thromboembolism and nonvalvular atrial fibrillation provide a framework for interpreting its clinical role and limitations.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-15

  This 2025 Cancer Letters review integrates tumor hypoxia, metabolic competition, and immune-cell dysfunction into a unified model of immunosuppressive tumor microenvironment formation. Its practical value lies in connecting HIF signaling and nutrient reprogramming with immune escape, while identifying metabolic vulnerabilities and experimental controls relevant to cancer research.

• ATM–Fenofibrate Synergy in Ovarian Cancer Cells

  2026-08-14

  The reference study identifies a metabolic vulnerability in high-grade serous ovarian cancer by showing that pharmacologic ATM inhibition synergizes with fenofibrate, a PPARα agonist, in HGSOC cell models. Its findings extend ATM-targeted research beyond conventional DNA-damaging combinations and suggest that induced cellular senescence may be especially relevant in HR-proficient disease.

• OSMI-1 O-GlcNAc Transferase Inhibitor Workflows

  2026-08-14

  OSMI-1 provides a cell-permeable, time-controlled way to reduce O-GlcNAcylation and interrogate stress, iron handling, and trophoblast phenotypes. This guide translates the HUWE1–TfR1 findings in preeclampsia research into practical dosing, target-engagement, and troubleshooting workflows while separating established evidence from proposed applications.

• Leptin (116-130), amide, mouse: Workflow Guide

  2026-08-13

  Build reproducible leptin-response assays with a sequence-defined mouse peptide fragment for metabolic, inflammatory, and energy-balance studies. This guide connects practical dosing and handling decisions with the SIRT6-AMPK/NLRP3 findings from a recent atrial-fibrillation model without overstating cross-domain evidence.

• TSPAN18–STIM1 Axis in Prostate Cancer Bone Metastasis

  2026-08-13

  Zhou et al. identify TSPAN18 as a binding partner that stabilizes STIM1 by opposing TRIM32-mediated ubiquitination, thereby enhancing store-operated Ca2+ entry and prostate cancer bone-metastatic behavior. The work provides a mechanistic framework for connecting protein turnover, calcium signaling, tumor-cell motility, and clinical metastatic risk.

578 records 9/39 page Previous Next First page 上5页 678910 下5页 Last page